Cutaneous Vasculitis after Radiotherapy
Abstract views: 120 / PDF downloads: 140
DOI:
https://doi.org/10.5152/EurJTher.2018.749Keywords:
Cutaneous vasculitis, hemangioma, radioimmunology, radiotherapyAbstract
Cutaneous vasculitis is a large heterogeneous group of diseases, where blood vessels are targeted by immunological and inflammatory reactions, which are the primary causes of this condition. Infections, medications, systemic collagenosis, chronic diseases, and malignancies are the secondary factors that cause cutaneous vasculitis. Hemangiomas are the most common primary benign tumors of the spinal cord and are rarely symptomatic. The most commonly manifested symptom is pain, but in rare cases, cutaneous vasculitis may lead to paraparesis and paralysis. Radiotherapy (RT) is a safe and effective treatment for symptomatic spinal cord hemangiomas. A 44-year-old male patient was admitted to our dermatology polyclinic with a complaint of a bilateral rash on both legs that had lasted for 1 week. The medical history of the patient included no disease other than a sacral hemangioma with
symptomatic pain, for which the patient had been treated with 4500 cGy curative radiotherapy 1 month previously. In our case, it was thought that cutaneous vasculitis was caused by the radiotherapy without any other triggering factor. A skin biopsy was taken to arrive at a definite diagnosis, and in the histopathological examination, abundant amounts of extra-red blood cells and lymphocytes were observed, along with endothelial profiling in superficial vessels; all of which are findings consistent with vasculitis. The patient was diagnosed with cutaneous vasculitis, both clinically and histopathologically. To the best of our knowledge, radiotherapy as a cause of vasculitis has been the subject of very few studies in the literature to date. In this regard, the present report describes a case of cutaneous vasculitis as a possible immune-related side effect of RT.
Metrics
References
Chung L, Kea B, Fiorentino DF. Cutaneous vasculitis. Dermatology. Eds. Bolognia JL, Jorizzo JL, Rapini RP. Spain, Elsevier, 2008; 347-67.
Aich RK, Deb AR, Banerjee A, Karim R, Gupta P. Symptomatic vertebral hemangioma: treatment with radiotherapy. J Cancer Res Ther 2010; 6: 199-203.
Marzano AV, Vezzoli P, Berti E. Skin involvement in cutaneous and systemic vasculitis. Autoimm Rev 2013; 12: 467-76.
Hall E, Cox J. Physical and biological basis of radiation therapy. In: Cox J, Ang K, editors. Radiation oncology. St. Louis: Mosby; 2003. p.3-62.
Miszczyk L, Ficek K, Trela K, Spindel J. The efficacy of radiotherapy for vertebral hemangiomas. Neoplasma 2001; 48: 82-4.
Archambeau JO, Hauser D, Shymko RM. Swine basal cell proliferation during a course of daily irradiation, five days a week for six weeks (6000 rad). Int J Radiat Oncol Biol Phys 1988; 15: 1383-8.
Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 2010; 70: 5679-85.
Peter RU. Diagnosis and Treatment of Cutaneous Radiation Injuries. In: Panizzon RG, Seegenschmiedt MH, editors. Radiation treatment and radiation reactions in dermatology. 2nd ed. Berlin: Springer; 2015. pp.185-8.
Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 2014; 4: 325.
Andros G, Schneider PA, Harris RW, Dulawa LB, Oblath RW, SallesCunha SX. Management of arterial occlusive disease following radiation therapy. Cardiovasc Surg 1996; 4: 135-42.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 European Journal of Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.